The Growing Role of Wearable Devices in U.S. Clinical Research

Introduction

Wearable technologies such as smartwatches, biosensors, continuous glucose monitors, and electronic patches are transforming the conduct of clinical trials in the United States. By capturing real-time physiological and behavioral data, wearables enable decentralized and patient-centric trial models. The U.S. Food and Drug Administration (FDA) has increasingly recognized the potential of wearable devices in supporting digital endpoints, safety monitoring, and real-world data collection. This article explores the regulatory framework, applications, case studies, and best practices for integrating wearables into U.S. clinical research.

Background / Regulatory Framework

FDA Guidance on Digital Health Technologies

In December 2023, FDA released guidance on “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.” This document outlines validation, usability, and data integrity expectations for wearables used in clinical trials. Sponsors must demonstrate analytical validity, clinical relevance, and patient usability.

ICH and Global Alignment

ICH E6(R2) GCP emphasizes accurate and reliable data capture, which applies directly to wearable use. FDA also collaborates with EMA and PMDA to align approaches for digital health technologies in multinational trials.

Case Example—Cardiology Trial

A U.S. cardiology trial used wearable ECG patches for continuous monitoring of arrhythmias. FDA accepted the data as exploratory endpoints, provided the sponsor validated device accuracy and data integrity.

Core Clinical Trial Insights

1) Digital Endpoints from Wearables

Wearables generate digital endpoints such as step count, heart rate variability, sleep quality, and gait analysis. FDA requires evidence of clinical meaningfulness and validation before regulatory acceptance.

2) Continuous Safety Monitoring

In early-phase trials, wearables provide continuous safety monitoring, enabling real-time detection of adverse events such as arrhythmias, hypoglycemia, or abnormal activity patterns.

3) Patient-Centric Trial Models

Wearables reduce patient burden by allowing remote participation and minimizing site visits, supporting decentralized clinical trials (DCTs).

4) Data Integrity and Part 11 Compliance

Wearable-generated data must meet FDA’s data integrity expectations, including secure transmission, audit trails, and compliance with 21 CFR Part 11 for electronic records.

5) Technology Validation

Sponsors must establish analytical validation (accuracy and precision), clinical validation (relevance to disease outcomes), and usability validation (patient adherence and device reliability).

6) Interoperability and Data Integration

FDA expects sponsors to address interoperability between wearable devices, electronic health records (EHRs), and electronic data capture (EDC) systems.

7) Patient Adherence

Ensuring patients wear and use devices correctly is critical. Training, reminders, and user-friendly interfaces are necessary to maintain high adherence rates.

8) CRO and Vendor Partnerships

CROs increasingly specialize in wearable data management. Sponsors must audit CRO processes to ensure compliance with regulatory requirements.

9) Case Studies of Adoption

FDA has reviewed trials in oncology, neurology, and cardiology using wearable endpoints. Acceptance depends on validation and alignment with study objectives.

10) Future Outlook

Artificial intelligence (AI) and machine learning applied to wearable data will enable predictive analytics, supporting early detection of disease progression and enhancing regulatory decision-making.

Best Practices & Preventive Measures

Sponsors should: (1) validate devices rigorously; (2) engage FDA early regarding wearable endpoints; (3) ensure interoperability and cybersecurity; (4) establish SOPs for device use; (5) train patients effectively; (6) monitor adherence remotely; (7) implement quality assurance programs for wearable data; (8) conduct pilot studies before pivotal trials; (9) engage with patient advocacy groups; and (10) prepare inspection-ready documentation of wearable integration.

Scientific & Regulatory Evidence

Key references include FDA’s 2023 guidance on digital health technologies, 21 CFR Part 11 requirements, ICH E6(R2) GCP, and EMA guidance on digital endpoints. Together, these form the regulatory foundation for wearable use in U.S. trials.

Special Considerations

Wearables are particularly valuable in rare disease and pediatric trials, where traditional assessments may be burdensome. FDA requires sponsors to adapt validation strategies to these populations.

When Sponsors Should Seek Regulatory Advice

Sponsors should seek FDA advice during pre-IND or End-of-Phase 2 meetings when proposing wearable-derived endpoints as primary or key secondary outcomes. Early discussions reduce risk of regulatory rejection.

Case Studies

Case Study 1: Oncology Wearable Biomarkers

In a U.S. oncology trial, wearable actigraphy was used to measure fatigue and activity levels. FDA accepted these measures as secondary endpoints, supporting overall trial outcomes.

Case Study 2: Diabetes Remote Monitoring

A diabetes trial deployed continuous glucose monitors (CGMs) linked to smartphones. FDA accepted the data for exploratory endpoints, emphasizing validation and patient adherence.

Case Study 3: Neurology Gait Analysis

A neurology trial applied wearable sensors to measure gait speed and balance. FDA accepted these data to complement traditional clinical assessments, demonstrating openness to digital biomarkers.

FAQs

1) What types of wearables are used in U.S. clinical trials?

Smartwatches, biosensors, patches, continuous glucose monitors, and activity trackers.

2) Are wearable endpoints accepted by FDA?

Yes, when validated and aligned with trial objectives, FDA accepts wearable endpoints as supportive or exploratory measures.

3) What are FDA’s key concerns with wearable data?

Data integrity, validation, patient adherence, and interoperability with trial systems.

4) Do wearables support decentralized clinical trials?

Yes, wearables enable remote data capture and reduce patient site visits.

5) What validation is required for wearables?

Analytical, clinical, and usability validation are required before regulatory acceptance.

6) How do sponsors ensure patient adherence?

By training participants, providing reminders, and designing user-friendly interfaces.

7) What role do CROs play in wearable adoption?

CROs provide specialized services for wearable integration, data management, and compliance with FDA expectations.

Conclusion & Call-to-Action

Wearables are redefining U.S. clinical trials by enabling continuous, real-world, and patient-centered data collection. Sponsors who validate devices, engage regulators early, and integrate wearable strategies effectively will gain a competitive advantage in trial efficiency, regulatory acceptance, and patient engagement. The future of U.S. clinical research is increasingly digital, with wearables at the forefront of transformation.